Stocktoria
Aclaris Therapeutics, Inc. ACRS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2015-10-07
Aclaris Therapeutics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -975.9% | -758.2% | -311.6% | -302.0% | -1327.1% |
| Net margin | -829.6% | -705.5% | -283.1% | -292.1% | -1344.0% |
| FCF margin | -603.4% | -107.9% | -254.8% | -229.1% | -775.7% |
| Return on assets | -40.5% | -59.9% | -44.8% | -34.1% | -36.2% |
| Return on equity | -63.0% | -84.9% | -56.3% | -44.0% | -46.0% |
| Current ratio | 3.36 | 3.99 | 4.16 | 10.55 | 8.94 |
| Revenue growth | -58.2% | -40.1% | 5.0% | 340.1% | 4.3% |
Source: SEC EDGAR filings · CIK 0001557746 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.